Wassmer, Evangeline;
Billaud, Charly;
Absoud, Michael;
Abdel-Mannan, Omar;
Benetou, Christina;
Cummins, Carole;
Forrest, Katharine;
... Wright, Sukhvir; + view all
(2024)
Long term outcome in non-multiple sclerosis paediatric acquired demyelinating syndromes.
European Journal of Paediatric Neurology
10.1016/j.ejpn.2024.07.002.
(In press).
![[thumbnail of 1-s2.0-S1090379824000990-main.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
1-s2.0-S1090379824000990-main.pdf - Accepted Version Access restricted to UCL open access staff until 7 July 2025. Download (1MB) |
Abstract
Objectives: We aimed to study the risks of relapse and long term disability in children with non-MS acquired demyelinating syndromes (ADS). // Methods: In this prospective, multi-centre study, from the 14 UK pediatric neurology centres, children (<16 years) experiencing a first episode of ADS were recruited from 2010-2014. Case report forms were collected prospectively. // Results: A total of 269 children were recruited and followed up for a median of 7.2 years. Median age at onset was 9y (IQR 9.5-14.5, 126 females). At last follow-up, 46 (18%) had MS, 4 AQP4-Ab NMOSD and 206 (80%) had other ADS, of which 27 (13%) relapsed. Relapsing MOGAD was the diagnosis in 12/27, 6 were seronegative and 9 did not have antibodies tested. Frequency of relapse differed according to first presentation in non-MS ADS, being least likely in transverse myelitis (p=0.025). In the non-MS group, MOG-Ab was predictive of relapse (HR=8.42; p<0.001) occurring 8 times as often in the first year and decreasing over time. Long-term difficulties did not differ between children with monophasic vs relapsing diseases. // Conclusion: The risk of relapse in non-MS ADS depends on initial diagnosis, and MOG-Ab positivity. Long-term difficulties are observed regardless of relapses and are determined by presenting phenotype.
Archive Staff Only
 |
View Item |
